

AUTOBIOGRAPHICAL RESUME OF PROFESSOR FERDINANDO NICOLETTI

Table of content

<u>AUTOBIOGRAPHICAL RESUME OF PROFESSOR FERDINANDO NICOLETTI.....</u>	<u>2</u>
<u>PERSONAL INFORMATION.....</u>	<u>2</u>
<u>PROF. FERDINANDO NICOLETTI'S EXPERIENCE IN FOREIGN INSTITUTIONS.....</u>	<u>3</u>
<u>PROF. FERDINANDO NICOLETTI HAS ACTED AS EXTERNAL REVIEWER FOR THE FOLLOWING INSTITUTIONS.....</u>	<u>3</u>
<u>PROF. FERDINANDO NICOLETTI HAS PARTICIPATED AT THE FOLLOWING NATIONAL AND EUROPEAN PROJECTS:.....</u>	<u>4</u>
<u>PROF. FERDINANDO NICOLETTI HAS BEEN COLLABORATING TO R&D IN PRECLINICAL AND CLINICAL STUDIES WITH PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES</u>	<u>4</u>
<u>PROF. FERDINANDO NICOLETTI HAS ACTED AND ACTS AS REVIEWER FOR THE FOLLOWING JOURNALS.....</u>	<u>5</u>
<u>PROF. FERDINANDO NICOLETTI IS IN THE EDITORIAL BOARD OF THE FOLLOWING JOURNALS.....</u>	<u>6</u>
<u>PROF. FERDINANDO NICOLETTI' S COLLABORATIONS.....</u>	<u>6</u>
<u>PROF. FERDINANDO NICOLETTI'S MAIN FIELD OF INTEREST.....</u>	<u>7</u>
<u>PROF. FERDINANDO NICOLETTI'S PATENTS.....</u>	<u>8</u>
<u>PROFESSOR FERDINANDO NICOLETTI'S PUBLICATIONS.....</u>	<u>8</u>

AUTOBIOGRAPHICAL RESUME OF PROFESSOR FERDINANDO NICOLETTI

Personal information

Name: Ferdinando

Surname: Nicoletti

Address: Via Luigi Sturzo, 3 - Acicastello (CT) – 95021 - Italy

Phone: +39 347 3369125

E-mail: ferdinic@unict.it

Prof. Ferdinando Nicoletti was born in Catania, Italy, in June 5th 1963 and **graduated in Medicine and Surgery** at the University of Catania in October 30th 1987 with a final mark of 110/110 with honours.

He obtained his **residency in Allergology and Clinical Immunology** at the Institute of Internal Medicine, Infectious Diseases and Immunopathology at the University of Milan in October 1990.

He has been **Assistant to Professor at the Institute of Microbiology** of the Faculty of Medicine and Surgery at the University of Milan from 1991 to 2001.

He became **Associate Professor of General Pathology** in July 2001 and has been serving in this role at the University of Catania from November 2001 to January 2007.

He has become **Full Professor of Medical Laboratory Sciences** on July 26th, 2006. He is Full Professor of Medical Laboratory Sciences at the School of Medicine of the University of Catania since February 2007.

Prof. Ferdinando Nicoletti has been **Vice-President of ethical committee** of Cannizzaro Hospital in Catania during 2009.

Prof. Ferdinando Nicoletti is currently **President of IACUC** of the University of Catania.

Prof. Ferdinando Nicoletti is **Scientific Committee Member** of **Scuola Superiore di Catania**.

Prof. Ferdinando Nicoletti is **cofounder of OncoNOx ApS** (www.onconox.com), Copenhagen, Denmark

Prof. Ferdinando Nicoletti's experience in foreign Institutions

Prof. Ferdinando Nicoletti is **external consultant at the Institute for Inflammation Research, Rigshospitalet University Hospital**, Copenhagen, Denmark, since 1999. He has been **Visiting Professor at the School of Medicine of the University of Belgrade, Serbia**, on 2004 and he is currently **Visiting Professor at the Tblisi State Medical University**.

Prof. Ferdinando Nicoletti has acted as external reviewer for the following Institutions

Swiss National Science Foundation

United States-Israel Binational Science Foundation,

Foundation Compagnia San Paolo

Datamonitor

Prof. Ferdinando Nicoletti has participated at the following national and European projects:

1. Development of carbon monoxide releasing molecules for the treatment of rheumatoid arthritis (EU Seventh Framework Programme)
2. Strategie di uso di batteri probiotici, prodotti batterici e parassitari per la terapia di malattie autoimmuni e allergiche. (Istituto superiore di sanità)
3. Hardis (VALUTAZIONE DELL'ATTIVITA' IMMUNOMODULANTE DELLA TRANSFERRINA UMANA E DEL SUO IMPIEGO NELLA TERAPIA DI PATOLOGIE AUTOIMMUNI E INFIAMMATORIE.)(FAR)
4. Bausch & Lomb (Evaluation of the effects of systemic administration of cloricromene in a model of streptozotocin-induced diabetes in rat) (FAR)
5. Cosmo (VALUTAZIONE DELLA POTENZIALE ATTIVITA' ANTIANDROGENA LOCALE E SISTEMICA DI NUOVI DERIVATI DEL CORTEXOLONE, E DELLA LORO POTENZIALE ATTIVITA' SUL SISTEMA IMMUNITARIO) (MIUR)
6. Effetti del trattamento con GITR:Fc nel modello di diabete di tipo 1 indotto in topi C57Bl6 da dosi multiple di streptozotocina (PRIN)

**Prof. Ferdinando Nicoletti has been collaborating to R&D in preclinical and clinical studies
with pharmaceutical and biotechnology Companies**

Ablynx N.V. (Zwijnarde, Belgium)

Alfama (Lisbon, Portugal)

Amgen Inc., (Thousand Oaks, CA)

Androclus Therapeutics (San Diego, CA)

Cosmo Biotech, Lainate (MI) /San Diego (CA)

Hoffman-La Roche, Basel Switzerland

Leo Pharmaceutical, Ballerup, Denmark
Merck Serono International SA (Geneva, Switzerland)
Merck-Schering-Plough, New Jersey, USA
Novartis, Basel, Switzerland
Pfizer-Wyeth , NY, USA
Puleva Biotech, Granada, Spain
Sanofi-Aventis, Labège, France

Prof. Ferdinando Nicoletti has acted and acts as reviewer for the following journals

Acta Paediatrica
Basic and Clinical Toxicology & Pharmacology
Cancer Letter
Cancer Research
Diabetologia
Diabetes
Endocrinology
European Journal of Pharmacology
Exp. Biol. Med
International Journal of Immunopharmacology
Journal of Chemotherapy
Journal of Immunological Methods
Journal of Molecular Medicine
Journal Pharmacology and Experimental Therapeutic
PLOS One
PNAS

Prof. Ferdinando Nicoletti is in the Editorial Board of the following journals

Int. J. Molecular Medicine

Int. J. of Oncology

Recent Pat Antiinfect Drug Discov

Journal of Carcinogenesis

Prof. Ferdinando Nicoletti' s collaborations

Prof. Yousef AL-ABED, Laboratory of Medicinal Chemistry, The Feinstein Institute for Medical Research, Manhasset, NY 11030, USA.

Prof. Salvatore ALBANI, Departments of Medicine and Pediatrics, University of California, San Diego, 9500

Prof. Klaus BENDTZEN, Institute of Medical Immunology, Rigshospitalet, Copenhagen, Denmark

Prof. Karsten BUSCHARD Bartholin Institutet, Rigshospitalet, 2100 Copenhagen, Denmark.

Prof. Mogens CLAESSION, Laboratory of Cellular Immunology, Department of International Health, Immunology and Microbiology, The Panum Institute, University of Copenhagen

Prof. Anne COOKE, Department of Pathology, Cambridge, UK

Dr. Ramon GOMIS, Endocrinology and Nutrition Unit, Hospital Clinic of Barcelona, Villaroel, Barcelona, Spain.

Prof. Masahiro ITOH , Deaprtment of Anatomy, Kagawa Medical University, Japan

Prof. PierLuigi Meroni, Pini Institute of Rheumatology, University of Milan, Italy

Dr Stellan SANDLER , Department of Medical Cell Biology, Uppsala University, Sweden

Professor Yehuda SHOENFELD, Dept. of Medicine B, Sheba Medical Center, Tel-Hashomer, 52621, Israel

Dr. John SIMS, Amgen, Boulder, CO

Prof. Stanislava STOSIC-GRUJICIC, Department of Immunology, Institute for Biological Research Sinisa Stankovic, Belgrade, Serbia and Montenegro.

Prof. Ferdinando Nicoletti's main field of interest

Prof. Ferdinando Nicoletti has been working in the field of cellular and molecular immunology, immunopharmacology, toxicology and experimental oncology. Prof. Nicoletti's area of research has primarily focused on the development of novel approaches for the treatment of cancer and immunoinflammatory diseases, probably of autoimmune origin, such as autoimmune thyroiditis, systemic lupus erythematosus, orchitis, hepatitis, rheumatoid arthritis, sepsis and type 1 diabetes. To this aim, Prof. Nicoletti. Nicoletti has mastered and has been using well known rodent models of these diseases.

By using these models, Prof. Nicoletti has evaluated in *in vitro*, *ex vivo* and *in vivo* conditions the immunopharmacological activities of novel immunosuppressive drugs (fusidic acid, deoxyspergaulin, FK506, thymopentin, pidotimod, VGX-1027), specific antagonists of proinflammatory cytokines (anti-IFN- γ antibody, soluble (s)IFN- γ receptor, sIL-1 receptor, sTNF receptor, anti-IL-12 antibody, IL-18 binding protein), anti-CD30L mAb or of exogenously-administered cytokines (IL-10, IFN γ). More recently, Prof. Nicoletti has also studied the chemotherapeutic profile of novel anti-cancer drugs in *in vitro* and *in vivo* preclinical settings. Prof. Nicoletti has also participated and supervised clinical studies on the effects of immunomodulatory compounds in patients with type 1 diabetes, Guillain Barrè syndrome, multiple sclerosis, HIV and renal cancer.

Prof. Ferdinando Nicoletti is in the *Top Italian Scientists of VIA-Academy* (http://www.topitalianscientists.org/Top_italian_scientists_VIA-Academy.aspx). He has published more than 170 papers in peer reviewed journals and has reached an H-index of 31.

Prof. Ferdinando Nicoletti's patents

1. **NICOLETTI F** (2010). ANTITUMOR PROPERTIES OF NO MODIFIED PROTEASE INHIBITORS. WO/2010/012466
2. **NICOLETTI F**, AL ABED Y, GAROTTA G (2007). (S,R)-3-Phenyl-4,5 dihydro-5-isoxazole acetic acid – nitric oxide and use thereof as anti-cancer and antiviral agent. WO/2008/138516
3. BAKHUTASHVILI V, HALLER J D, BAKHUTASHVILI I, BAKHUTASHVILI A, **NICOLETTI F**, THIRY M, PONCIN (2006). Amniotic-derived peptide and uses thereof. US20070123467
4. **NICOLETTI F** (2006). Compounds having immunomodulator activity. WO/2006/097273
5. SALVAGGIO A, **NICOLETTI F**, MACRI' B (2006). Use of uk114 in the treatment of leishmaniasis. US20060100142

Professor Ferdinando Nicoletti's publications

- 1) Nicoletti G., Olivieri S., Cammarata E., **Nicoletti F.**, Tempera G.: Le infezioni microbiche nel tossicodipendente. *Giornale di Batteriologia, Virologia ed Immunologia*, 1986, LXXIX, 124-143
- 2) **Nicoletti F.**, Di Mauro M., Stracuzzi S., Pane F., Steinsvag P.L.: Pevalenza di ICA e CF-ICA in familiari di diabetici di tipo 1. *Rassegna di Medicina Interna*, 1988, IX, 3-7
- 3) Lunetta M., Di Mauro M., La Bella G., Buttiglieri R., **Nicoletti F.**: The quick-acting effect of regular insulin is preserved in premixed protamine and soluble human insulin preparations. *Med. Sci. Res.* 17, 897-898, 1989.
- 4) **Nicoletti F.** Barcellini W., Di Mauro M., Steinsvag P.O., Lunetta M., Scalia G., Condorelli F., Stivala A.: Correlazione tra anticorpi anti betacellula pancreatica e anti cytomegalovirus in collaterali sani di diabetici di tipo 1. *G. Ital. Diabetol.*, 1989, 9, 165-166.

- 5) **Nicoletti F.**, Meroni P.L., Barcellini W., Steinsvag P.O., Di Mauro M., Lunetta M., Pagano M., Consoli U., Zanussi C.: Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. *Immunology Letters* 23, 211-216, 1989/90.
- 6) **Nicoletti F.**, Caruso M., Di Mauro M., Stracuzzi S., Mancuso M., Scuderi G., Leonardi C., Pagano M., Lunetta M.: CD3+CD25+ cells, CD3+CD4+/CD3+CD8+ ratio, HLA alloantigen association and ICA in type 1 (insulin-dependent) diabetes. *Med. Sci. Res.* 18, 679-681, 1990.
- 7) **Nicoletti F.**, Scalia G., Lunetta M., Condorelli F., Di Mauro M., Barcellini W., Stracuzzi S., Pagano M., Meroni P.L.: Correlation between islet cell antibodies and anti cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (insulin-dependent) diabetic patients. *Clin. Immunol. Immunopathol.*, 55, 139-147, 1990.
- 8) **Nicoletti F.**, Meroni P.L., Landolfo S., Gariglio M., Guzzardi S., Barcellini W., Lunetta M., Mughini L., Zanussi C.: Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma. *Lancet* 336, 319, 1990.
- 9) Barcellini W., Borghi M.O., **Nicoletti F.**, Bonara P., Fain C., Meroni P.L. Combination of mutant EL-4 thymoma cells and EBV-infection in B lymphocyte activation a) EBV-infection of EL-4-activated lymphocytes. b) Use of EL-4 cells as feeders for lymphoblastoid cell lines. *J. Clin. Lab. Immunol.*, 33, 21-28, 1990
- 10) **Nicoletti F.**, Scalia G., Condorelli F., Stivala A., Leonardi C., Mattina A., Steinsvag P.O., La Rosa L., Lunetta M.: Anti-cytomegalovirus IgM and IgG antibodies, islet cell antibodies and gamma interferon serum levels in newly diagnosed IDDM patients. *Int. J. Immunopathol. Pharmacol.*, 4, 99-106, 1991.
- 11) **Nicoletti F.**, Consoli U., Calogero D., Speciale A.M., Di Marco R., Leonardi C., La Rosa L., Lunetta M., Di Cataldo A., Meroni P.L.: Enhanced percentage of Leu M3+DR+ and Leu M3+CD25+ cells in newly diagnosed IDDM patients. *Autoimmunity*, 9, 255-259, 1991.

- 12) **Nicoletti F.**, Meroni P.L., Barcellini W., Grasso S., Borghi M.O., Lunetta M., Di Marco R., Stefani S., Mughini L.: FK-506 prevents diabetes in diabetes-prone BB/Wor rats. *Int. J. Immunopharmacol.* 13, 1027-1030, 1991.
- 13) **Nicoletti F.**, Meroni P.L., Lunetta M., Vigo R., Palermo T., Papalia D., Barcellini W., Di Mauro M., Caruso-Nicoletti M., Mughini L., Zanussi C.: Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. *Lancet* 337, 1292, 1991.
- 14) Lunetta M., Di Mauro M., **Nicoletti F.**, Mughini L.: Diabetogenic effect of naloxone in subjects with impaired glucose tolerance. *Med. Sci. Res.* 19, 737-738, 1991.
- 15) Barcellini W., Borghi M.O., Fain C., Del Papa N., **Nicoletti F.**, Meroni P.L. Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. *Clin Immunol. Immunopathol.*, 65, 39-44, 1992
- 16) **Nicoletti F.** Meroni P.L., Di Marco R., Grasso S., Barcellini W., Borghi M.O., Lunetta M., Mughini L., Menta R., Schorlemmer H.U., Zanussi C. The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. *Scand. J. Immunol.*, 36, 415-420, 1992
- 17) **Nicoletti F.**, Meroni P.L., Di Marco R., Barcellini W., Borghi M.O., Gariglio G., Mattina A., Grasso S., Landolfo S. In vivo treatment with monoclonal antibody to interferon-gamma neither affects the survival nor the rate and onset of lupus nephritis in the MRL/lpr-lpr mouse. *Immunopharmacology*, 24, 11-16, 1992
- 18) Del Papa N., Meroni P.L., Barcellini W., Sinico A., Radice A., Tincani A., D'Cruz D., **Nicoletti F.**, Borghi M.O., Khamashta M.A., Huges G.R.V., Balestrieri G. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. *Clin. Immunol. Immunopathol.* 63, 267-274, 1992
- 19) Borghi M.O., Barcellini W., Fain C., **Nicoletti F.**, Del Papa N., Licciardello L., Meroni P.L.: In vitro effect of MSD53 and its fractions on human mononuclear cells. *Int. J. Immunother.*, 8, 77-84, 1992

- 20) Di Marco R., Condorelli F., Girardello R., Uslenghi C., Chisari G., Di Mauro M., Speciale A.M., Meroni P.L., **Nicoletti F.** Increased rate of survival in *Streptococcus pneumoniae*-infected rats treated with the new immunomodulator Pidotimod. *Scand. J. Infect. Dis.* 24, 821-823, 1992
- 21) Lunetta M., Di Mauro M., **Nicoletti F.**, Mughini L.: Effects of naloxone on immunoreactive insulin and C-peptide response to intravenous glucagon in obese women. *Med. Sci. Res.* 21, 211-212, 1993.
- 22) Barcellini W., Borghi M.O., Fain C., **Nicoletti F.**, Menta R., Meroni P.L., Schorlemmer H.U., In vitro effects of deoxyspergualin (DSO) on human peripheral blood mononuclear cells. *EOS*, 13, 14-15, 1993
- 23) Di Marco R., Carrabba I., Cavallaro V., Zaccone P., Stazzone C., Franco S., Cocuzza C., Nicoletti G., **Nicoletti F.:** The effect of cefepime on some immune parameters in vitro: lack of interference with mitogen-induced lymphoproliferation, immunoglobulin synthesis, IFN-gamma and IL-2 secretion and IL-2 receptor expression. *J.Chemother.* 5, 297-301, 1993
- 24) **Nicoletti F.**, Borghi M.O., Meroni P.L., Barcellini W., Fain C., Di Marco R., Menta R., Schorlemmer H.U., Bruno G., Magro G.,Grasso S.: Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. *Clin. Exp. Immunol.*91, 232-236
- 25) Tang H., Mignon-Godefroy K., Meroni P.L., Garotta G., Charreire J., **Nicoletti F.** The effects of a monoclonal antibody to interferon-gamma on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. *Eur. J. Immunol.* 23 275-278, 1993
- 26) **Nicoletti F.**, Di Marco R., Barcellini W., Magro G., Schorlemmer H.U., Kurrle R., Lunetta M., Grasso S., Zaccone P., Meroni P.L. :Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. *Eur. J. Immunol.* 24 1843-1847, 1994
- 27) **Nicoletti F.**, Di Marco R., Morrone S., Zaccone P., Lembo D., Grasso S., Santoni A., Meroni P.L. Bendtzen K. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with

the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. *Immunology*. 81, 317-321, 1994

28) : **Nicoletti F.**, Di Marco R., Barcellini W., Borghi M.O., Lunetta M., Mughini L., Meroni P.L., Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. *Scand.J.Immunol.* 39, 333-336, 1994

29) Borghi M.O., Fain C., Barcellini W., Del Papa N., La Rosa L., **Nicoletti F.**, Uslenghi C., Meroni P.L. Ex vivo effects of pidotimod on peripheral blood mononuclear cell immune functions: study of an elderly population. *Int.J. Immunother.*, X, 35-39, 1994

30) Barcellini W., Brando B., Borghi M.O., Fain C., Rizzardi G.P., **Nicoletti F.**, Meroni P.L. Mutant EL-4 B5 subclone activation system: cytofluorimetric analysis of B lymphocyte surface markers. *J. Clin. Lab. Immunol.*, 43, 51-67, 1994

31) **Nicoletti F.**, Zaccone P., Magro G., Barcellini W., Cavallaro V., Belli G., Cocuzza C., Di Marco R., Meroni P.L. The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse. *Scand. J. Immunol.* 40, 549-56, 1994

32) Piona A., La Rosa L., Tincani A., Faden D., Magro G., Grasso S., **Nicoletti F.**, Balestrieri G., Meroni P.L.: Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti cardiolipin antibodies in pregnant naive BALB/c mice. *Scand J Immunol.*, 41, 427-32, 1995

33) Boissier M.C., Chiocchia G., Bessis N., Hajnal J., Garotta G., **Nicoletti F.**, Fournier C TI: Biphasic effect of interferon gamma in murine collagen induced arthritis. *Eur J Immunol.* 25, 1184-1190, 1995

34) **Nicoletti F.**, Zaccone P., Di Marco R., Magro G., Grasso S., Morrone S., Santoni A., Tempera G., Meroni P.L., Bendtzen K.: Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. *Immunology*, 85, 645-650, 1995

- 35) Barcellini W., Rizzardi G.P., Borghi M.O., **Nicoletti F.**, Fain C., Del Papa N., Meroni P.L.: In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. *Lupus*, 5, 139-145, 1996
- 36) **Nicoletti F.**, Patti F., Di Marco R., Zaccone P., Nicoletti A., Meroni P.L., Reggio A. Circulating levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. *Cytokine*, 8, 395-400, 1996
- 37) Genovese F., Mancuso G., Cuzzola M., Cusumano V., **Nicoletti F.**, Bendtzen K., Teti G.: Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. *Antimicrobial Agents and Chemotherapy*, 40, 1733, 1996
- 38) Di Marco R., Zaccone P., Magro G., Grasso S., Lunetta M., Barcellini W., Nicolosi V.M., Meroni P.L., **Nicoletti F.** Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats. *Clin. Exp. Immunol.*, 105, 338-343, 1996
- 39) **Nicoletti F.**, Borghi M.O., Barcellini W., Fain C., Beltrami B., Del Papa N., Schorlemmer H.U., Mottola R., Meroni P.L.: Immunosuppressive activity of 15-Deoxyspergaulin on normal and autoimmune peripheral blood mononuclear cells. *Eur. J. Pharmacol.*, 311, 213-220, 1996
- 40) Lunetta M., Di Mauro M, Le Moli R., **Nicoletti F.**:Effect of octreotide on blood glucose, and counterregulatory hormones in insulin-dependent diabetic patients: The role of dose and route of administration. *Eur. J. Clin. Pharmacol.*, 51, 139-144, 1996
- 41) **Nicoletti F.**, Patti F., Cocuzza C., P. Zaccone P., Nicoletti A., Di Marco R., Reggio A.:Elevated serum levels of IL-12 in chronic progressive multiple sclerosis. *Journal of Neuroimmunology*, 70, 87-90, 1996

- 42) **Nicoletti F.**, Meroni P.L. Bendtzen K. Fucidic acid and insulin-dependent diabetes mellitus. *Autoimmunity*, 24, 187-197, 1996
- 43) **Nicoletti F.**, Zaccone P., Di Marco R., et al. The effects of a nonimmunogenic form of murine soluble interferon-g receptor on the development of autoimmune diabetes in the NOD mouse. *Endocrinology*, 137: 5567-5575, 1996
- 44) **Nicoletti F.**, Zaccone P., Di Marco R., Lunetta M., Magro G., Grasso S., Meroni PL. and Garotta G. Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. *Endocrinology*, **138**: 281-288, 1997
- 45) **Nicoletti F.**, Mancuso G., Cusumano V., Di Marco R., Zaccone P., Bendtzen K. and Teti G. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. *Eur. J. Immunol.*, **27**: 1580-1583, 1997
- 46) Doth M., Fricke M., **Nicoletti F.**, Garotta G., Van Velthuysen M.-L., Bruijn J.A. and Gleichman E. Genetic differences in immune reactivity to mercuric chloride (HgCl₂): immunosuppression of H-2^d mice is mediated by interferon-gamma (IFN-gamma). *Clin. Exp. Immunol.*, **109**: 149-156, 1997
- 47) Nicoletti F., Beltrami B., Raschi E., Di Marco R., Magro G., Grasso S., Bendtzen K., Fiorelli G., Meroni PL. Protection from concanavalin A (ConA)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. *Clin. Exp. Immunol.*, 110: 479-484 , 1997
- 48) Lunetta M., Di Mauro M., Le Moli R. and **Nicoletti F.** Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 diabetic patients. *Diab. Res. Clin. Pract.*, 38: 81-89, 1997
- 49) **Nicoletti F.**, Mancuso G., Anzani Ciliberti F., Beninati C., Carbone M., Franco S., and Cusumano V. Endotoxin-induced lethality in neonatal mice is counteracted by interleukin-10 (IL-10) and exacerbated by anti-IL-10. *Clin.Diagn.Lab. Immunol.*, 4: 607-610 , 1997

- 50) Cocuzza C., Blandino G., Mattina R., **Nicoletti F.**, and Nicoletti G. Antibiotic susceptibility of group A streptococci in 2 Italian cities : Milano and Catania. *Microb. Drug. Resist.*, 1997, 3 : 379-384
- 51) **Nicoletti F.**, Zaccone P., Di Marco R., Magro G., Grasso S., Stivala F., Calori G., Mughini L., Meroni PL. and Garotta G. Paradoxical antidiabetogenic effect of gamma-Interferon in DP-BB rats. *Diabetes*, **47**:32-38, 1998
- 52) Itoh M., Yano A., Xie Q., Iwahashi K., Takeuchi Y., Meroni PL. and **Nicoletti F.** Essential pathogenic role for endogenous interferon-g (IFN-g) during disease onset phase of murine experimental autoimmune orchitis, I In vivo studies. *Clin. Exp. Immunol.*, 111: 513-520, 1998
- 53) Di Marco R., Zaccone P., Condorelli L., Leonardi C., Caccamo F., Di Mauro M., Meroni P., and **Nicoletti F.** Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor- α . *Immunology Letters.*, 61: 63-66, 1998
- 54) Ikematsu W., Luan F.L., La Rosa L., Beltrami B., **Nicoletti F.**, Buyon J.P., Meroni PL., Balestrieri G., and Casali P. Human anticardiolipin monoclonal antibodies cause placental necrosis and fetal loss in BALB/c mice. *Arthr. Rheum.*, 41: 1026-1039 , 1998
- 55) **Nicoletti F.**, Di Marco R., Patti F., Reggio E., Nicoletti A., Zaccone P., Stivala F., Meroni PL., and Reggio A. Blood levels of transforming growth factor-beta 1 (TGF- β 1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta-1b (IFN- β 1b). *Clin. Exp. Immunol.*, 113: 96-99, 1998
- 56) **Nicoletti F.**, Nicoletti A., Giuffrida S., Di Marco R., Meroni PL., Bendtzen K., Lunetta M. Sodium fusidate in Guillain-Barré syndrome: a case report. *J. Neurol. Neurosurg. Psychiatry*, 65: 266-268, 1998

- 57) Amital H., Levi Y., Blank M., Barak V., Langevitz P., Afek A., **Nicoletti F.**, Koplovic J., Gilburd B., Meroni PL., and Shoenfeld Y. Immunomodulation of murine experimental SLE-like disease by interferon-gamma. *Lupus*, 7: 445-454, 1998
- 58) Calogero AE., **Nicoletti F.**, Palumbo MA., Burrello N., Di Mauro M., Lunetta M., Bendtzen K., and Cianci A. Macrophage-derived cytokines in the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin-6 and low levels of granulocyte-macrophage colony-stimulating factor. *Cytokine*, 10: 814-818, 1998
- 59) Xiang M., Zacccone P., Di Marco R., Magro S., Di Mauro M., Beltrami B., Meroni PL., and **Nicoletti F.** Prevention by rolipram of concanavalin A-induced T-cell dependent hepatitis in mice. *Eur. J. Pharmacol.*, 367: 399-404, 1999
- 60) La Mantia I., Grillo C., Mattina T., Zacccone P., Xiang M., Di Mauro M., Meroni PL., and **Nicoletti F.** Prophylaxis with the novel immunomodulator Pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome. *J. Chemother.*, 11: 126-130, 1999
- 61) Brazillet M-P., Batteux F., Abeshira-Amar O., **Nicoletti F.**, and Charreire J. Induction of experimental autoimmune thyroiditis by heat-denaturated porcine thyroglobulin: a Tc1-mediated disease. *Eur. J. Immunol.*, 29: 1342-1352, 1999
- 62) Xiang M., Zacccone P., Di Marco R., Harris R., Magro G., Di Mauro M., Meroni PL., Garotta G., and **Nicoletti F.** Failure of exogenously administered interferon-gamma or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice. *Autoimmunity*, 30: 71-80, 1999
- 63) Zacccone P., Phyllips J., Conget I., Gomis R., Haskins K., Minty A., Bendtzen K., Cooke A., and **Nicoletti F.** Interleukin-13 prevents autoimmune diabetes in NOD mice. *Diabetes*, 48: 1522-1529, 1999

- 64) Panerai AE., Sacerdote P., Bianchi M., **Nicoletti F.**, Manfredi B., Gaspani L., Bartorelli A., Ceciliani F., Ronchi S. Chronic administration of UK-114, a multifunctional emerging protein, modulates the Th1/Th2 cytokine pattern and experimental autoimmune diseases. *Ann. NY Acad. Sci.*, 876 : 229-235, 1999
- 65) **Nicoletti F.**, Di Marco R., Zaccone P., Magro G., Di Mauro M., Grasso S., and Meroni PL. Endogenous interleukin-12 only plays a key pathogenetic role in NOD mouse diabetes during the very early stage of the disease. *Immunology*, 97: 367-370, 1999
- 66) Zaccone P., Hutchings P., **Nicoletti F.**, Penna G., Adorini L., and Cooke A. The involvement of IL-12 in murine experimentally induced autoimmune thyroid disease. *Eur. J. Immunol.*, 29: 1933-1942, 1999
- 67) Di Marco R., Khademi M., Wallstrom E., Muhallab S., **Nicoletti F.**, and Olsson T. Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): suppression of IFN-gamma and TNF-alpha and enhancement of IL-10. *J. Autoimmun.*, 13: 187-195, 1999
- 68) **Nicoletti F.**, Zaccone P., Conget I., Gomis R., Moller C., Meroni PL., Bendtzen K., Trepicchio W., and Sandler S. Early prophylaxis with recombinant human Interleukin-11 prevents spontaneous diabetes in NOD mice. *Diabetes*, 48: 2333-2339, 1999
- 69) **Nicoletti F.**, Patti F., Nicoletti A., L' Episcopo MR., Di Marco R., Bendtzen K., and Reggio A. Sodium fusidate in steroid resistant relapses of multiple sclerosis. *Multiple Sclerosis*, 5 : 377, 1999
- 70) Di Marco R., Xiang M., Zaccone P., Leonardi C., Franco S., Meroni PL., and **Nicoletti F.** Concanavalin A-induced hepatitis in mice is prevented by Interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. *Autoimmunity*, 31 : 75-83, 1999
- 71) **Nicoletti F.**, Di Marco R., Zaccone P., Xiang M., Magro G., Grasso S., Morrone S., Santoni A., Shoenfeld Y., Garotta G., and Meroni PL. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. *Eur. J. Immunol.*, 30 : 438-447, 2000

- 72) **Nicoletti F.**, Zacccone P., Xiang M., Magro G., Di Mauro M., Di Marco R., Garotta G., and Meroni PL. Essential pathogenetic role for interferon (IFN)-gamma in Concanavalin A-induced T cell dependent hepatitis: Exacerbation by exogenous IFN-g and prevention by IFN-greceptor Immunoglobulin fusion protein. *Cytokine*, 12 : 315-323, 2000
- 73) **Nicoletti F.**, Di Marco R., Patti F., Zacccone P., L'Episcopo MR., Reggio E., Xiang M., Nicoletti A., and Reggio A. Short-term treatment of relapsing remitting multiple sclerosis patients with Interferon (IFN)-beta 1b transiently increases the blood levels of Interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1 β , IL-2, IL-4, and tumor necrosis factor- α . *Cytokine*, 12 : 682-687, 2000
- 74) Papaccio G., **Nicoletti F.**, Pisanti FA., Bendtzen K., and Galdieri M. Prevention of spontaneous autoimmune diabetes by transferring in vitro antigen-pulsed dendritic cells. *Endocrinology*, 141 : 1500-1505, 2000
- 75) Gorrie MJ., Qasim FJ., Whittle CJ., Gillespie KM., Szeto C-C., **Nicoletti F.**, Bolton EM., Bradley JA., and Mathieson PW. Exogenous type 1 cytokines Interferon-gamma and Interleukin-12 suppress the Th2 response induced by mercuric chloride. *Clin. Exp. Immunol.*, 121 ; 17-22, 2000
- 76) Meroni PL., Raschi E., Camera M., Testoni C., **Nicoletti F.**, Tincani A., Khamastha MA., Balestrieri G., Tremoli E., Hess DC. Endothelial activation by aPL : a potential pathogenetic mechanism for clinical manifestation of the syndrome. *J. Autoimmun.*, 15 : 237-240, 2000
- 77) **Nicoletti F.**, Di Marco R., Patti F., Nicoletti A., Leonardi C., Reggio E., Meroni PL., and Reggio A. The antiinflammatory cytokine Interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta 1b treatment, that neither moodifies its ex vivo secretion from peripheral blood mononuclear cells. *Autoimmunity*, 32 : 265-270, 2000
- 78) **Nicoletti F.**, Di Marco R., Zacccone P., Salvaggio A., Magro G., Bendtzen K., and Meroni PL. Murine concanavalin A-induced hepatitis is prevented by interleukin (IL)-12 antibody and

exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. *Hepatology*, 32 : 728-733, 2000

79) **Nicoletti F.**, Di Marco R., Conget I., Gomis R., Edwards C. III., Papaccio G., Bendtzen K., and Sandler S. Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. *J. Autoimmunity*, 15 : 395-405, 2000

80) **Nicoletti F.**, Conget I., Di Marco R., Speciale A.M., Morinigo R., Bendtzen K., and Gomis R. Serum levels of the interferon-gamma -inducing cytokine interleukin-18 are increased in individuals at high risk of developing type 1 diabetes. *Diabetologia*, 44 : 309-311, 2001

81) Di Marco R., Puglisi G., Papaccio G., Nicoletti A., Patti F., Reggio A., Bendtzen K., and **Nicoletti F.** Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. *Multiple Sclerosis*, 7: 101-104, 2001

82) Di Marco R., Khademi M., Walstrom E., Iacobus E., Salvaggio A., Caracappa S., Papoian R., **Nicoletti F.**, and Olsson T. Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis. *J. Neuroimmunol.*, 116: 168-177, 2001

83) Panerai AE., **Nicoletti F.**, Sacerdote P., Arvidsson L., Conget I., Gomis R., Bartorelli A. and Sandler S. MFP14, a multifunctional emerging protein with immunomodulatory properties, prevents spontaneous and recurrent autoimmune diabetes in NOD mice. *Diabetologia*, 44 : 839-847, 2001

84) **Nicoletti F.**, Di Marco R., Patti F., Reggio E., Nicoletti A., Bendtzen K., and Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis. *Neurology*, 57 : 342-344, 2001

85) **Nicoletti F.**, Di Marco R., Sacerdote P., Meroni PL., Mangano K., Edwards C. III, Bartorelli A., Bendtzen K., and Panerai A. Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14. *Antimicrobial Agents and Chemotherapy*, 45: 1591-1594, 2001

- 86) Patti F., Cataldi ML., **Nicoletti F.**, Reggio E., Nicoletti A., and Reggio A. Combination therapy with cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. *J. Neurol Neurosurg. Psychiatr.* 71: 404-407, 2001
- 87) Ablake M., Itoh M., Kaneko T., Iimura A., Nakamura Y., Meroni P., and **Nicoletti F.** Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice. *Eur. J. Pharmacol.*, 23, 450: 209-212, 2002
- 88) **Nicoletti F.**, Conget I., Di Mauro M., Mazzarino MC., Bendtzen K., Messina A., and Gomis R. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type 1 diabetes mellitus patients and subjects at risk of developing the disease. *Diabetologia*, 45: 1107-1110, 2002
- 89) Papaccio G., **Nicoletti F.**, Pisanti FA., Galdieri M., and Bendtzen K. An imidazoline compound completely counteracts interleukin-1 [beta] toxic effects to rat pancreatic islet [beta] cells *Mol. Med.*, 9: 536-545, 2002
- 90) Drage M., Zaccone P., Phillips JM., **Nicoletti F.**, Dawson J., Andrew Bradley J., and Cooke A. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevents autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. *Transplantation*, 74: 611-619, 2002
- 91) Li L., Itoh M., Ablake M., Nacri B., Benbdtzen K., and **Nicoletti F.** Prevention of murine experimental autoimmune orchitis by recombinant human interleukin-6. *Clin. Immunol.*, 102: 135-137, 2002
- 92) Zaccone P., Fehervari Z., Blanchard L., **Nicoletti F.**, Edwards CC 3rd, and Cooke A. Autoimmune thyroid disease induced by thyroglobulin and lipopolysaccharide is inhibited by soluble TNF receptor type 1. *Eur. J. Immunol.*, 32: 1021-1028, 2002
- 93) Besong G, Battaglia G, D'Onofrio M, Di Marco R, Ngomba RT, Storto M, Castiglione M, Manganano K, Busceti CL, **Nicoletti FR**, Bacon K, Tusche M, Valenti O, Conn PJ, Bruno V, Nicoletti F. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in gli-

- al cell cultures. *J. Neurosci.*, 22: 5403-11, 2002
- 94) Recasens M., Aguilera E., Morinigo R., Casamitjana R., **Nicoletti F.**, Gomis R., and Conget I. Insulin lipro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. *Diabetes Res. Clin. Pract.*, 3: 153-159, 2003
- 95) **Nicoletti F.**, Di Marco RD, Papaccio G., Conget I., Gomis R., Bernardini R., Sims JE., Shoenfeld Y., and Bendtzen K. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulinitis by a recombinant IL-18-binding protein: Fc construct. *Eur. J. Immunol.*, 8: 2278-2286, 2003
- 96) Kaneko T., Itoh M., Nakamura Y., Iimura A., Hayashi S., Takahashi K., Stivala F., Bendtzen K., and Nicoletti F. Proinflammatory effects of exogenously administered IL-10 in experimental autoimmune orchitis. *Cytokine*, 22: 50-53, 2003
- 97) Di Marco R., Mangano K., Quattrocchi C., Musumeci R., Speciale AM., Papaccio G., Buschard K., Bendtzen K., and **Nicoletti F.** Curative effects of sodium fusidate on the development of dinitrobenzene sulfonic acid (DNB)-induced colitis in rats. *Clin. Immunol.*, 109: 266-271, 2003
- 98) Cantarella G., Risuglia N., Lombardo G. Lempereur L., **Nicoletti F.**, Memo M., and Bernardini R. Protective effects of estradiol on TRAIL-induced apoptosis in human oligodendrocytic cell line: evidence for multiple sites of interactions. *Cell Death Differ.*, 11: 503-511, 2004
- 99) Lgssiar A., Hassan M., Schott-Ohly P., Friesen N., **Nicoletti F.**, Trepicchio WL., and Gleichmann H. Interleukin-11 inhibits NF-kappaB and AP1 activation in islets and prevents diabetes induced with streptozotocin in mice. *Exp. Biol. Med.*, 229: 425-436, 2004
- 100) Di Paola R., Di Marco R., Mazzon E., Genovese T., Bendtzen K., Macri B., **Nicoletti F.**, and Cuzzocrea S. Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal, *Clin. Immunol.*, 113: 64-73, 2004

- 101) [Di Marco R](#), [Mangano K](#), [Quattrocchi C](#), [Amato F](#), [Nicoletti F](#), [Buschard K](#). Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet. [APMIS](#). 2004 Oct;112(10):651-5.
- 102) [Aguilera E](#), [Casamitjana R](#), [Ercilla G](#), [Oriola J](#), [Nicoletti F](#), [Gomis R](#), [Conget I](#). Clinical characteristics, beta-cell function, HLA class II and mutations in MODY genes in non-paediatric subjects with Type 1 diabetes without pancreatic autoantibodies. *Diabet Med*. 22:137-43, 2005
- 103) Zacccone P, Phillips J, Conget I, Cooke A, **Nicoletti F**. IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse. *Clin Immunol*. 115:74-9, 2005
- 104) Papaccio G, Graziano A, Valiante S, D'Aquino R, Travali S, **Nicoletti F**. Interleukin (IL)-1beta toxicity to islet beta cells: Efaroxan exerts a complete protection. *J Cell Physiol*. 203:94-102, 2005
- 105) De Carvalho Bittencourt M, Herren S, Graber P, Vilbois F, Pasquali C, Berney C, Plitz T, **Nicoletti F**, Kosco-Vilbois MH. Extracellular lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetes. *Eur J Immunol*. 35:1501-9, 2005
- 106) Cvetkovic I, Al-Abed Y, Milijkovic D, Maksimovic-Ivanic D, Roth J, Bacher M, Lan HY, **Nicoletti F**, Stosic-Grujicic S. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. *Endocrinology* 146:2942-51, 2005
- 107) Conget I, Aguilera E, Pellitero S, Naf S, Bendtzen K, Casamitjana R, Gomis R, **Nicoletti F**. Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial. *Diabetologia*. 48:1464-8, 2005.
- 108) Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, **Nicoletti F**, Metz CN, Pavlov VA, Miller EJ, Tracey KJ. ISO-1 binding to the tau-

tomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. *J Biol Chem*. 2005 Nov 4;280(44):36541-4. Epub 2005 Aug 22.

109) Auci D, **Nicoletti F**, Mangano K, Pieters R, Nierkens S, Morgan L, Offner H, Frincke J, Reading C. Anti-inflammatory and Immune Regulatory Properties of 5-Androsten-3{beta}, 17{beta}-Diol (HE2100), and Synthetic Analogue HE3204: Implications for Treatment of Autoimmune Diseases. *Ann N Y Acad Sci*. 1051:730-42, 2005

110) **Nicoletti F**, Creange A, Orlikowski D, Bolgert F, Mangano K, Metz C, Di Marco R, Al Abed Y. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. *J Neuroimmunol*. 2005 Nov;168:168-74.

111) Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, **Nicoletti F**, Stivala F, McCubrey JA, Mazzarino MC. Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. *Cancer Biol Ther*. 2005; 4:1192-4.

112) Celasco G, Moroa L, Bozzella R, Ferraboschi P, Bartorelli L, Di Marco R, Quattrocchi C, **Nicoletti F**. Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity. *Arzneimittelforschung*. 2005;55:581-7.

113) Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, Di Marco R, Signorelli S, Scalia G, Zignego AL, De Re V, Mazzarino MC, **Nicoletti F**. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. *Oncol Rep*. 2006;15:1305-8.

114) [Malaguarnera L](#), [Di Rosa M](#), [Zambito AM](#), [dell'Ombra N](#), **Nicoletti F**, [Malaguarnera M](#) Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. *Gut* 2006, 55:1313-20.

115) Stosic-Grujicic S, Cvetkovic I, Mangano K, Fresta M, Maksimovic-Ivanic D, Harhaji L, Popadic D, Momcilovic M, Miljkovic D, Kim J, Al-Abed Y, **Nicoletti F**. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accel-

erated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. *J Pharmacol Exp Ther.* 2007, 320:1038-49.

116) Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, Donia M, Al Abed Y, Kim J, **Nicoletti F**, Stosic-Grujicic S, Claesson M. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. *Clin Immunol.* 2007;123:311-23.

117) Perdichizzi A, **Nicoletti F**, La Vignera S, Barone N, D'Agata R, Vicari E, Calogero AE Effects of tumour necrosis factor-alpha on human sperm motility and apoptosis. *J Clin Immunol.* 2007 Mar;27(2):152-62.

118) Aljabari B, Calogero AE, Perdichizzi A, Vicari E, Karaki R, Lahloub T, Zatarri R, El-Abed K, **Nicoletti F**, Miller EJ, Pavlov VA, Al-Abed Y. Imbalance in seminal fluid MIF indicates male infertility. *Mol Med.* 2007 Mar-Apr;13(3-4):199-202.

119) Dati G, Quattrini A, Bernasconi L, Malaguti MC, Antonsson B, Nicoletti F, Alliod C, Di Marco R, Sagot Y, Vitte PA, Hiver A, Greco B, Roach A, Zaratin PF. Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. *J Neuroimmunol.* 2007 Oct;190(1-2):8-17.

120) Galle P, Jensen L, Andersson C, Cuzzocrea S, Di Paola R, **Nicoletti F**, Svenson M, Bendtzen K, Thomsen AR, Hansen MB. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. *Int Immunopharmacol.* 2007 Dec 15;7(13):1704-13. Epub 2007 Sep 21.

121) Claesson MH, **Nicoletti F**, Stosic-Grujicic S, Doria A, Zampieri S. Interactions between infections and immune-inflammatory cells in type 1 diabetes mellitus and inflammatory bowel diseases: evidences from animal models. *Clin Exp Rheumatol.* 2008 Jan-Feb;26(1 Suppl 48):S8-11. Review.

- 122) Maksimovic-Ivanic D, Mijatovic S, Harhaji L, Miljkovic D, Dabideen D, Fan Cheng K, Mangano K, Malaponte G, Al-Abed Y, Libra M, Garotta G, **Nicoletti F**, Stosic-Grujicic S. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. *Mol Cancer Ther.* 2008 Mar;7(3):510-20.
- 123) Mangano K, Dati G, Quattrocchi C, Proietti L, Mazzarino C, Di Marco R, Bendtzen K, Greco B, Zaratin P, **Nicoletti F**. Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barrè syndrome. *J Neuroimmunol.* 2008 May 30;196(1-2):107-15.
- 124) Mangano K, Sardesai N, D'Alcamo M, Libra M, Malaguarnera L, Donia M, Bendtzen K, Meroni P, **Nicoletti F**. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. *Eur J Pharmacol.* 2008 May 31;586(1-3):313-21.
- 125) Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, Miljkovic D, Metz C, Mangano K, Papaccio G, Al-Abed Y, **Nicoletti F**. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. *J Cell Physiol.* 2008 Jun;215(3):665-75.
- 126) Mijatovic S, Maksimovic-Ivanic D, Mojic M, Malaponte G, Libra M, Cardile V, Miljkovic D, Harhaji L, Dabideen D, Cheng KF, Bevelacqua Y, Donia M, Garotta G, Al-Abed Y, Stosic-Grujicic S, **Nicoletti F**. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. *Nitric Oxide.* 2008 Sep;19(2):177-83.
- 127) Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, **Nicoletti F**, Stivala F, Zignego AL, Carbone A. Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. *J Hepatol.* 2008 Aug;49(2):170-4.
- 128) Stosic-Grujicic S, Stojanovic I, **Nicoletti F**. MIF in autoimmunity and novel therapeutic approaches. *Autoimmun Rev.* 2008 Aug 19. [Epub ahead of print]

- 129) Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, **Nicoletti F**, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. *Expert Opin Ther Targets*. 2008 Sep;12(9):1139-65.
- 130) McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, Bäsecke J, Troppmair J, Libra M, **Nicoletti F**, Molton S, McMahon M, Evangelisti C, Martelli AM. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. *Leukemia* 2008 Nov;22(11):2080-90.
- 131) Mangano K, Sardesai NY, Quattrocchi C, Mazzon E, Cuzzocrea S, Bendtzen K, Meroni PL, Kim JJ, **Nicoletti F**. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. *Br J Pharmacol*. 2008 Nov;155(5):722-30.
- 132) Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, **Nicoletti F**, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. *Leukemia*. 2009 Jan;23(1):25-42.
- 133) **Nicoletti F**, Lamenta C, Donati S, Spada M, Ranazzi A, Cacopardo B, Mangano K, Belardelli F, Perno C, Aquaro S. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. *Clin Exp Immunol*. 2009 Jan;155(1):28-34.
- 134) Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojisavljevic N, **Nicoletti F**, Drulovic J. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. *J Neuroimmunol*. 2009 Feb 15;207(1-2):101-6.
- 135) Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, **Nicoletti F**, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. *Cell Cycle*. 2009 May 1;8(9):1352-8. Review.

- 136) Malaguarnera M, Di Rosa M, **Nicoletti F**, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. *J Mol Med*. 2009 Jul;87(7):679-95. Review.
- 137) Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, Dabideen D, Cheng KF, McCubrey JA, Mangano K, Al-Abed Y, Libra M, Garotta G, Stosic-Grujicic S, **Nicoletti F**. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. *Mol Cancer Ther*. 2009 May 5. [Epub ahead of print]
- 138) Donia M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Mangano K, Tumino S, Biondi A, Basile F, Al-Abed Y, Stosic-Grujicic S, **Nicoletti F**. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. *Eur J Pharmacol*. 2009 Aug 1;615(1-3):228-33.
- 139) Donia M, Mangano K, Amoroso A, Mazzarino MC, Imbesi R, Castrogiovanni P, Coco M, Meroni P, **Nicoletti F**. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. *J Autoimmun*. 2009 Sep;33(2):135-40.
- 140) Ahlem C, Auci D, Mangano K, Reading C, Frincke J, Stickney D, **Nicoletti F**. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. *Ann N Y Acad Sci*. 2009 Sep;1173:781-90.
- 141) **Nicoletti F**, Conrad D, Wang A, Pieters R, Mangano K, van Heeckeren A, White SK, Frincke J, Reading CL, Auci DL, Stickney D. 16alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. *Clin Exp Immunol*. 2009 Dec;158(3):308-16.
- 142) McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, **Nicoletti F**, Libra M, Martelli AM, Montalto G, Cervello M. [Emerging Raf inhibitors](#). *Expert Opin Emerg Drugs*. 2009 Dec;14(4):633-48. Review.

- 143) Mangano K, Nicoletti A, Patti F, Donia M, Malaguarnera L, Signorelli S, Magro G, Muzio V, Greco B, Zaratin P, Meroni P, Zappia M, **Nicoletti F**. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. *Clin Exp Immunol*. 2010 Feb;159(2):159-68.
- 144) Castellano G, Torrisi E, Ligresti G, **Nicoletti F**, Malaponte G, Travali S, McCubrey JA, Canevari S, Libra M. Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. *Cell Cycle*. 2010 Feb 6;9(3).
- 145) Mijatovic S, Maksimovic-Ivanic D, Timotijevic G, Miljkovic D, Donia M, Libra M, Coco M, McCubrey J, Al-Abed Y, Korac A, Stosic-Grujicic S, **Nicoletti F**. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. *Free Radic Biol Med* 2010 Jan 28. [Epub ahead of print]
- 146) Auci DL, Mangano K, Destiche D, White SK, Huang Y, Boyle D, Frincke J, Reading CL, **Nicoletti F**. Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis. *Int J Mol Med* 2010 Apr 25 625-33
- 147) Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, **Nicoletti F**, Libra M, Martelli AM, McCubrey JA. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. *Cell Cycle*. 2010 Apr 10;9(8).
- 148) Libra M, Polesel J, Russo AE, De Re V, Cinà D, Serraino D, **Nicoletti F**, Spandidos DA, Stivala F, Talamini R. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? *Int J Oncol*. 2010 Jun;36(6):1331-40. Review.
- 149) [McCubrey JA](#), [Steelman LS](#), [Abrams SL](#), [Chappell WH](#), [Russo S](#), [Ove R](#), [Milella M](#), [Tafari A](#), [Lunghi P](#), [Bonati A](#), [Stivala F](#), [Nicoletti F](#), [Libra M](#), [Martelli AM](#), [Montalto G](#), [Cervello M](#). Emerging MEK inhibitors. [Expert Opin Emerg Drugs](#). 2010 Jun;15(2):203-23.

- 150) Abrams SL, Steelman LS, Shelton JG, Chappell W, Bäsecke J, Stivala F, Donia M, **Nicoletti F**, Libra M, Martelli AM, McCubrey JA. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. *Cell Cycle*. 2010 May;9(9):1839-46.
- 151) Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, **Nicoletti F**, Libra M, Martelli AM, McCubrey JA. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. *Cell Cycle*. 2010 May;9(9):1781-91.
- 152) Donia M, Cacopardo B, Libra M, Scalia G, McCubrey JA, **Nicoletti F**. New perspectives in HCV therapy: entry inhibitors. *Recent Pat Antiinfect Drug Discov*. 2010 Nov 1;5(3):181-94.
- 153) Ahlem CN, Page TM, Auci DL, Kennedy MR, Mangano K, **Nicoletti F**, Ge Y, Huang Y, White SK, Villegas S, Conrad D, Wang A, Reading CL, Frincke JM. Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols. *Steroids*. 2011 Jan;76(1-2):145-55. Epub 2010 Oct 23.
- 154) Conrad D, Wang A, Pieters R, **Nicoletti F**, Mangano K, van Heeckeren AM, White SK, Frincke JM, Reading CL, Stickney D, Auci DL. HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression. *J Inflamm (Lond)*. 2010 Oct 30;7:52.
- 155) Donia M, Mangano K, Quattrocchi C, Fagone P, Signorelli S, Magro G, Sfacteria A, Bendtzen K, **Nicoletti F**. Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents. *Scand J Immunol*. 2010 Nov;72(5):396-407.
- 156) Mijatovic S, Maksimovic-Ivanic D, Mojic M, Timotijevic G, Miljkovic D, Mangano K, Donia M, Cataldo AD, Al-Abed Y, Cheng KF, Stosic-Grujicic S, **Nicoletti F**. Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. *J Cell Physiol*. 2010 Nov 10.

- 157) Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, **Nicoletti F**, Cinatl J. Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells. *Neoplasia*. 2010 Dec;12(12):1023-30.
- 158) **Nicoletti F**, Auci DL, Mangano K, Flores-Riveros J, Villegas S, Frincke JM, Reading CL, Offner H. 5-androstenediol ameliorates pleurisy, septic shock, and experimental autoimmune encephalomyelitis in mice. *Autoimmune Dis*. May 18;2010:757432. 2010
- 159) Fagone P, Mangano K, Quattrocchi C, Motterlini R, Di Marco R, Magro G, Penacho N, Romao CC, **Nicoletti F**. Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. *Clin Exp Immunol*. 2011 Jan 14.
- 160) [Donia M](#), [Maksimovic-Ivanic D](#), [Mijatovic S](#), [Mojic M](#), [Miljkovic D](#), [Timotijevic G](#), [Fagone P](#), [Caponnetto S](#), [Al-Abed Y](#), [McCubrey J](#), [Stosic-Grujicic S](#), **Nicoletti F**. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. [Cell Cycle](#). 2011 Feb 1;10(3). [Epub ahead of print]
- 161) McCubrey JA, Steelman LS, Kempf CR, Chappell W, Abrams SL, Stivala F, Malaponte G, **Nicoletti F**, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. [Therapeutic Resistance Resulting from Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways](#). *J Cell Physiol*. 2011 Feb 1. doi: 10.1002/jcp.22647. [Epub ahead of print]
- 162) Kosiewicz MM, Auci DL, Fagone P, Mangano K, Caponnetto S, Tucker CF, Azeem N, White SK, Frincke JM, Reading CL, **Nicoletti F**. [HE3286, an orally bioavailable synthetic analogue of an](#)

[active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic \(NOD\) mouse.](#) Eur J Pharmacol. 2011 Feb 28. [Epub ahead of print]

163) [Nicoletti A](#), [Fagone P](#), [Donzuso G](#), [Mangano K](#), [Dibilio V](#), [Caponnetto S](#), [Bendtzen K](#), [Zappia M](#), [Nicoletti F](#). Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. [Cytokine](#). 2011 May 6. [Epub ahead of print]

164) Ahlem CN, Auci DL, **Nicoletti F**, Pieters R, Kennedy MR, Page TM, Reading CL, Enioutina EY, Frincke JM. [Pharmacology and immune modulating properties of 5-androstene-3 \$\beta\$,7 \$\beta\$,17 \$\beta\$ -triol, a DHEA metabolite in the human metabolome.](#) J Steroid Biochem Mol Biol. 2011 May 5. [Epub ahead of print]

165) [Donia M](#), [Anzaldi M](#), [Di Marco R](#), [Libra M](#), [Mangano K](#), [Fagone P](#), [Galvagna S](#), [Di Gregorio P](#), [Nicoletti F](#). Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. [Int J Mol Med](#). 2011 May 20. doi: 10.3892/ijmm.2011.703. [Epub ahead of print]

166) **Nicoletti F**, Fagone P, Meroni P, McCubrey J, Bendtzen K. mTOR as a multifunctional therapeutic target in HIV infection. *Drug Discov Today*. 2011 Aug;16(15-16):715-21. Epub 2011 May 23. PubMed PMID: 21624501.

167) Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, **Nicoletti F**, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. *Oncotarget*. 2011 Jul;2(7):538-50. PubMed PMID: 21730367

168) Canducci F, Ceresola ER, Saita D, Al-Abed Y, Garotta G, Clementi M, **Nicoletti F**. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistin-

guishable from those of the parental compound saquinavir. *Antiviral Res.* 2011 Sep;91(3):292-5. Epub 2011 Jul 8.

169) Di Rosa M, Malaguarnera M, **Nicoletti F**, Malaguarnera L. Vitamin D3: a helpful immunomodulator. *Immunology.* 2011 Oct;134(2):123-39. doi: 10.1111/j.1365-2567.2011.03482.x. Review. PubMed PMID: 21896008

170) McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Bäsecke J, **Nicoletti F**, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM. Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. *Curr Pharm Des.* 2012 Jan 19.

171) Fagone P, Mangano K, Coco M, Perciavalle V, Garotta G, Romao CC, **Nicoletti F**. Therapeutic potential of carbon monoxide in multiple sclerosis. *Clin Exp Immunol.* 2012 Feb;167(2):179-87. doi: 10.1111/j.1365-2249.2011.04491.x. Review. 168)

172) Mojic M, Mijatovic S, Maksimovic-Ivanic D, Dinic S, Grdovic N, Miljkovic D, Stosic-Grujicic S, Tumino S, Fagone P, Mangano K, Zocca MB, Alabed Y, McCubrey JA, **Nicoletti F**. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. *Cell Cycle.* 2012 Mar 15;11(6).

173) Maksimovic-Ivanic D, Stosic-Grujicic S, **Nicoletti F**, Mijatovic S. Resistance to TRAIL and how to surmount it. *Immunol Res.* 2012 Mar 11

174) Donia M, Mangano K, Fagone P, De Pasquale R, Dinotta F, Coco M, Padron J, Al-Abed Y, Giovanni Lombardo GA, Maksimovic-Ivanic D, Mijatovic S, Zocca MB, Perciavalle V, Stosic-Grujicic S, **Nicoletti F**. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. *Oncol Rep.* 2012 Aug;28(2):682-8

- 175) Mangano K., Fagone P., Di Mauro M., Ascione E., Maiello V., Milicic T., Jotic A., Lalic N.M., Saksida T., Stojanovic I., Selmi C., Farina C., Stosic-Grujicic S., Meroni P., **Nicoletti F.** The immunobiology of apotransferrin in type 1 diabetes. *Clin Exp Immunol.* 2012 Sep;169(3):244-252
- 176) Fagone P, Di Rosa M, Palumbo M, De Gregorio C, **Nicoletti F**, Malaguarnera L. Modulation of heat shock proteins during macrophage differentiation. *Inflamm Res.* 2012 Oct;61(10):1131-9
- 177) Stojanovic I, Saksida T, Nikolic I, **Nicoletti F**, Stosic-Grujicic S. Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro. *Clin Exp Immunol.* 2012 Aug;169(2):156-63
- 178) Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA, Nicoletti F. Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells. *Basic Clin Pharmacol Toxicol.* 2012 Jul 4. doi: 10.1111/j.1742-7843.2012.00923.x. [Epub ahead of print]
- 179) Mojic M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F. Therapeutic Potential of NO-Modified Drugs in Colon Cancer Cells. *Mol Pharmacol.* 2012 Jul 13. [Epub ahead of print]

Catania, 17/09/2012

Ferdinando Nicoletti